Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective
Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA.
Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
Janssen Res & Dev, Discovery Sci, Computat Chem, Beerse, Belgium.
Temple Univ, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA.
Show others and affiliations
2018 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 104, no 5, p. 818-835Article, review/survey (Refereed) Published
Abstract [en]

Membrane transporters play diverse roles in the pharmacokinetics and pharmacodynamics of small-molecule drugs. Understanding the mechanisms of drug-transporter interactions at the molecular level is, therefore, essential for the design of drugs with optimal therapeutic effects. This white paper examines recent progress, applications, and challenges of molecular modeling of membrane transporters, including modeling techniques that are centered on the structures of transporter ligands, and those focusing on the structures of the transporters. The goals of this article are to illustrate current best practices and future opportunities in using molecular modeling techniques to understand and predict transporter-mediated effects on drug disposition and efficacy. Membrane transporters from the solute carrier (SLC) and ATP-binding cassette (ABC) superfamilies regulate the cellular uptake, efflux, and homeostasis of many essential nutrients and significantly impact the pharmacokinetics of drugs(1-4); further, they may provide targets for novel therapeutics as well as facilitate prodrug approaches.(5,6) Because of their often broad substrate selectivity they are also implicated in many undesirable and sometimes life-threatening drug-drug interactions (DDIs).(5,6)

Place, publisher, year, edition, pages
John Wiley & Sons, 2018. Vol. 104, no 5, p. 818-835
National Category
Pharmacology and Toxicology Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-369940DOI: 10.1002/cpt.1174ISI: 000448068500012PubMedID: 29981151OAI: oai:DiVA.org:uu-369940DiVA, id: diva2:1272248
Funder
NIH (National Institute of Health), R01 GM108911, R01 DK061425Åke Wiberg FoundationAvailable from: 2018-12-18 Created: 2018-12-18 Last updated: 2022-10-31Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Matsson, Pär

Search in DiVA

By author/editor
Matsson, Pär
By organisation
Department of Pharmacy
In the same journal
Clinical Pharmacology and Therapeutics
Pharmacology and ToxicologyPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 72 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf